Assessment of Diagnostic Utility, Clinical Phenotypic Associations, and Prognostic Significance of Anti-NXP2 Autoantibody in Patients with Idiopathic Inflammatory Myopathies: a Systematic Review and Meta-analysis

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2020 Jul 19

PMID 32681367

Citations 7

Authors

Liubing Li

Chenxi Liu

Linlin Cheng

Songxin Yan

Haizhen Chen

Yongzhe Li

Affiliations

Soon will be listed here.

Abstract

The objectives of this study are to analyze the association between anti-nuclear matrix protein 2 (NXP2) autoantibody and idiopathic inflammatory myopathies (IIMs) and to assess the diagnostic and prognostic relevance of anti-NXP2 autoantibody in patients with IIMs. A systematic search was performed in PubMed, Web of Science, EMBASE, the Cochrane Library, and Scopus to identify studies published as of February 29, 2020. Data was analyzed using Stata 12.0 and Meta-DiSc 1.4. Twenty-eight studies (4764 patients with IIMs and 1981 controls) were included in the meta-analysis. Anti-NXP2 autoantibody showed a significant association with IIMs (odds ratio (OR) = 26.36, 95% confidence interval (CI): 12.05-57.67, P < 0.001), especially juvenile IIMs (OR = 62.48, 95% CI: 16.97-229.98, P < 0.001). The pooled sensitivity, specificity, and area under the curve were 0.19 (95% CI = 0.16-0.21), 1.00 (95% CI = 1.00-1.00), and 0.95 for patients with juvenile IIMs versus controls. Anti-NXP2 autoantibody was associated with an increased risk of developing five characteristics (edema, muscle weakness, myalgia/myodynia, dysphagia, and calcinosis) and reduced risk of interstitial lung disease (ILD) (P < 0.001). Anti-NXP2 autoantibody showed no association with increased risk of death in IIMs (P = 0.463). These findings suggest that anti-NXP2 autoantibody is specially related to IIMs and is related to edema, muscle weakness, myalgia/myodynia, dysphagia, calcinosis, and ILD in patients with IIMs. However, there is no evidence to suggest that the presence of anti-NXP2 autoantibody confers a poor prognosis with respect to overall survival. Key Points • This study summarized the diagnostic and prognostic accuracies of anti-NXP2 autoantibody for patients with IIMs. Anti-NXP2 autoantibody is related to edema, muscle weakness, myalgia/myodynia, dysphagia, calcinosis, and ILD in patients with IIMs.

Citing Articles

NXP-2 positive dermatomyositis with marked dysphagia following an insect bite.

Bombardi L, Scorza C, Finsterer J, Scorza F Clinics (Sao Paulo). 2024; 79:100420.

PMID: 38991369 PMC: 11295917. DOI: 10.1016/j.clinsp.2024.100420.

A bibliometric analysis of the research status and trends in studies on polymyositis and dermatomyositis with interstitial lung disease from 2000 to 2022 using Web of Science.

Ma X, Feng W, Chen S, Zhong X, Zheng X, Lin C Immun Inflamm Dis. 2024; 12(2):e1190.

PMID: 38376948 PMC: 10878432. DOI: 10.1002/iid3.1190.

Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies.

Ghirardello A, Gatto M, Franco C, Zanatta E, Padoan R, Ienna L Diagnostics (Basel). 2023; 13(19).

PMID: 37835823 PMC: 10572214. DOI: 10.3390/diagnostics13193080.

Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies.

Choi M, Satoh M, Fritzler M Curr Opin Rheumatol. 2023; 35(6):383-394.

PMID: 37503636 PMC: 10552841. DOI: 10.1097/BOR.0000000000000957.

Presentation and clinical course of pediatric-onset versus adult-onset Takayasu arteritis-a systematic review and meta-analysis.

Misra D, Rathore U, Kopp C, Patro P, Agarwal V, Sharma A Clin Rheumatol. 2022; 41(12):3601-3613.

PMID: 35927524 DOI: 10.1007/s10067-022-06318-5.

References

Betteridge Z, McHugh N . Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2015; 280(1):8-23. DOI: 10.1111/joim.12451. View

McHugh N, Tansley S . Autoantibodies in myositis. Nat Rev Rheumatol. 2018; 14(5):290-302. DOI: 10.1038/nrrheum.2018.56. View

Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szollosi L, Danko K . Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev. 2014; 13(12):1211-9. DOI: 10.1016/j.autrev.2014.08.011. View

Bohan A, Peter J . Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292(8):403-7. DOI: 10.1056/NEJM197502202920807. View

Bohan A, Peter J . Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7):344-7. DOI: 10.1056/NEJM197502132920706. View

Sontheimer R . Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?. J Am Acad Dermatol. 2002; 46(4):626-36. DOI: 10.1067/mjd.2002.120621. View

Hoogendijk J, Amato A, Lecky B, Choy E, Lundberg I, Rose M . 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004; 14(5):337-45. DOI: 10.1016/j.nmd.2004.02.006. View

Lundberg I, Tjarnlund A, Bottai M, Werth V, Pilkington C, de Visser M . 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017; 76(12):1955-1964. PMC: 5736307. DOI: 10.1136/annrheumdis-2017-211468. View

Griggs R, Askanas V, DiMauro S, Engel A, Karpati G, Mendell J . Inclusion body myositis and myopathies. Ann Neurol. 1995; 38(5):705-13. DOI: 10.1002/ana.410380504. View

10.

Connors G, Christopher-Stine L, Oddis C, Danoff S . Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?. Chest. 2010; 138(6):1464-74. DOI: 10.1378/chest.10-0180. View

11.

Ye L, Zuo Y, Yang H, Li W, Peng Q, Lu X . Specific Autoantibodies and Clinical Phenotypes Correlate with the Aberrant Expression of Immune-Related MicroRNAs in Dermatomyositis. J Immunol Res. 2019; 2019:2927061. PMC: 6399529. DOI: 10.1155/2019/2927061. View

12.

Li S, Ge Y, Yang H, Wang T, Zheng X, Peng Q . The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. Clin Rheumatol. 2019; 38(8):2171-2179. DOI: 10.1007/s10067-019-04503-7. View

13.

Li L, Wang H, Wang Q, Wu C, Liu C, Zhang Y . Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease. J Neurol Sci. 2019; 397:123-128. DOI: 10.1016/j.jns.2018.12.040. View

14.

Wang L, Huang L, Yang Y, Chen H, Liu Y, Liu K . Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay. Clin Rheumatol. 2018; 37(10):2731-2739. DOI: 10.1007/s10067-018-4216-x. View

15.

Ueki M, Kobayashi I, Takezaki S, Tozawa Y, Okura Y, Yamada M . Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies. Mod Rheumatol. 2018; 29(2):351-356. DOI: 10.1080/14397595.2018.1452353. View

16.

Best M, Jachiet M, Molinari N, Manna F, Girard C, Pallure V . Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients. J Eur Acad Dermatol Venereol. 2017; 32(7):1164-1172. DOI: 10.1111/jdv.14759. View

17.

Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y . Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther. 2017; 19(1):259. PMC: 5702134. DOI: 10.1186/s13075-017-1469-8. View

18.

Tansley S, Simou S, Shaddick G, Betteridge Z, Almeida B, Gunawardena H . Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun. 2017; 84:55-64. PMC: 5656106. DOI: 10.1016/j.jaut.2017.06.007. View

19.

Merlo G, Clapasson A, Cozzani E, Sanna L, Pesce G, Bagnasco M . Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets. Arch Dermatol Res. 2016; 309(2):87-95. DOI: 10.1007/s00403-016-1704-1. View

20.

Fredi M, Bartoli F, Cavazzana I, Ceribelli A, Carabellese N, Tincani A . Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. Clin Exp Rheumatol. 2016; 35(2):303-308. View